{"schema_version":"secwatch.filing_event.v1","accession":"0000014272-24-000094","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.366934+00:00","generated_at":"2026-06-03T07:47:43.059875+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bristol-Myers Squibb Q1 revenue up 5% to $11.9B; GAAP loss per share $5.89 on acquired IPRD charges","bullets":["Q1 revenues $11,865M (+5% reported, +6% ex-FX); growth portfolio revenues $4,767M (+8%, +11% ex-FX).","GAAP loss per share ($5.89); Non-GAAP loss per share ($4.40); includes $6.30/share impact from acquired IPRD and licensing.","Completed acquisitions of Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune collaboration.","Announced strategic productivity initiative targeting ~$1.5B in cost savings, majority reinvested for innovation.","Updated 2024 non-GAAP EPS and line-item guidance to reflect recent transactions; Abecma and Breyanzi received new U.S. approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0000014272-24-000094","json":"https://secwatch.observer/filing/0000014272-24-000094.json","markdown":"https://secwatch.observer/filing/0000014272-24-000094.md","text":"https://secwatch.observer/filing/0000014272-24-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000001427224000094/0000014272-24-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000001427224000094/bmy-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:47:43.059875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7e3c8bfa3a976d21b8a290f7d5a76bea0d02cb1","claim":"BRISTOL MYERS SQUIBB CO reported the first quarter of 2024 results: revenue $11,865, EPS (5.89).","evidence_excerpt":"get the most promising medicines to patients as quickly as possible.\" 1 First Quarter $ in millions, except per share amounts 2024 2023 Change Change Excl. F/X** Total Revenues $11,865 $11,337 5 % 6 % (Loss)/Earnings Per Share — GAAP* (5.89) 1.07 N/A N/A (Loss)/Earnings Per Share — Non-GAAP* ** (4.40) 2.05 N/A N/A Acquired IPRD charge and Licensing Income Net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/14272/000001427224000094/0000014272-24-000094-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Revenue","value":"$11,865"},{"label":"EPS","value":"(5.89)"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}